[Combined treatment in patients with carcinoma in situ of the urinary bladder using intravesical pirarubicin, irradiation and hyperthermia].

Nihon Gan Chiryo Gakkai shi Pub Date : 1990-11-20
T Takechi, M Kawamura, H Nakagawa, S Inatsuki, K Akiyama, M Yano, Y Sumiyoshi, K Mandai, S Moriwaki, M Kataoka
{"title":"[Combined treatment in patients with carcinoma in situ of the urinary bladder using intravesical pirarubicin, irradiation and hyperthermia].","authors":"T Takechi,&nbsp;M Kawamura,&nbsp;H Nakagawa,&nbsp;S Inatsuki,&nbsp;K Akiyama,&nbsp;M Yano,&nbsp;Y Sumiyoshi,&nbsp;K Mandai,&nbsp;S Moriwaki,&nbsp;M Kataoka","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The treatment with hyperthermia in combination with radiation and intravesical pirarubicin (THP-ADM) was preliminary investigated in 5 patients with urinary bladder carcinoma in situ. Following intravesical administration of 30 mg THP-ADM, external irradiation of 3.0 Gy was delivered to the urinary bladder. Immediately then, hyperthermia using Thermotron RF-8 was performed for 50 min (intravesical temperature: 42-43 degrees C for 35 min). After five courses of the treatment, complete response has been maintained for 6, 8, and 9 months in 3 patients. However, in a patient with complete response, urinary cytology became positive in the 6th month after the treatment. In the remaining patient treatment was interrupted after only 3 courses due to urinary irritation, urinary cytology didn't become negative. The side effects of the combined treatment were limited to the transient symptoms of bladder irritation in all patients and thermal burn in 2 patients. These preliminary results suggest that this combined treatment may represent an effective conservative therapy for patients with urinary bladder carcinoma in situ.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 11","pages":"2724-7"},"PeriodicalIF":0.0000,"publicationDate":"1990-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Gan Chiryo Gakkai shi","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The treatment with hyperthermia in combination with radiation and intravesical pirarubicin (THP-ADM) was preliminary investigated in 5 patients with urinary bladder carcinoma in situ. Following intravesical administration of 30 mg THP-ADM, external irradiation of 3.0 Gy was delivered to the urinary bladder. Immediately then, hyperthermia using Thermotron RF-8 was performed for 50 min (intravesical temperature: 42-43 degrees C for 35 min). After five courses of the treatment, complete response has been maintained for 6, 8, and 9 months in 3 patients. However, in a patient with complete response, urinary cytology became positive in the 6th month after the treatment. In the remaining patient treatment was interrupted after only 3 courses due to urinary irritation, urinary cytology didn't become negative. The side effects of the combined treatment were limited to the transient symptoms of bladder irritation in all patients and thermal burn in 2 patients. These preliminary results suggest that this combined treatment may represent an effective conservative therapy for patients with urinary bladder carcinoma in situ.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[膀胱内注射吡柔比星、放射和热疗联合治疗膀胱原位癌]。
对5例原位膀胱癌患者进行热疗联合放疗及膀胱内注射吡柔比星(THP-ADM)治疗的初步探讨。膀胱内给药30 mg THP-ADM后,膀胱外照射3.0 Gy。然后立即使用Thermotron RF-8进行热疗50分钟(膀胱温度:42-43℃,持续35分钟)。在5个疗程的治疗后,3例患者的完全缓解维持了6个月、8个月和9个月。然而,在完全缓解的患者中,尿细胞学在治疗后6个月变为阳性。其余患者仅在3个疗程后因尿路刺激中断治疗,尿细胞学检查未变为阴性。联合治疗的副作用局限于所有患者的短暂性膀胱刺激症状和2例患者的热烧伤。这些初步结果表明,这种联合治疗可能是膀胱原位癌患者的一种有效的保守治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Chemoembolization therapy with lipiodol, cisplatin and etoposide for hepatocellular carcinoma]. [Relationship between human papillomavirus and oncogenes (c-myc, N-myc) amplification in human cervical cancers]. [Treatment of liver metastatic ovarian cancer with sequential administration of OK-432 and etoposide]. Flow cytometric analysis of nuclear DNA content in patients with recurrent epithelial ovarian cancer. [The effect on prognosis and the adverse drug reaction of intermittent cisplatin therapy in advanced ovarian cancer patients].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1